

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

The claims have been amended as kindly suggested by the Examiner with the exception of deleting the term "pharmaceutical" from claim 10.

It is respectfully submitted that the term "pharmaceutical" is appropriate for claim 10. The Examiner kindly stipulates that the data presented in the specification shows the claimed compounds can inhibit elastase *in vitro*, and stipulates that inhibition of elastase will occur *in vivo* as well. The specification contains experimental examples demonstrating the use of the claimed compounds *in vivo* using animal models. See for example Experiments 2 and 3 on pages 22-25 of the specification. The specification further contains a detailed description of the dosage of the present compounds and their administration forms. Please see page 26 of the specification.

In summary, it is respectfully submitted that one skilled in the art would be capable of using the claimed compounds in a pharmaceutical composition without undue experimentation taking into consideration the teachings of the specification and the high level of skill in the medical arts.

Favorable reconsideration and allowance is respectfully solicited.

Respectfully submitted,

Fuminori SATO et al.

By: Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 12, 2004